Fda declines emergency use authorization for zyesami® (aviptadil) for subgroup of patients with critical covid-19 at immediate risk of death from respiratory failure despite treatment with approved therapy, including remdesivir

Focus is now on nrx-101 for bipolar depression with suicidality radnor, pa. , july 1, 2022 /prnewswire/ -- nrx pharmaceuticals, inc. (nasdaq: nrxp), ("nrx pharmaceuticals"), a clinical-stage biopharmaceutical company, today announced that the us food and drug administration (fda) has declined to issue an emergency use authorization (eua) for zyesami® (aviptadil) for a sub-group of patients that in addition to zyesami®, also received remdesivir and continued to progress.
NRXP Ratings Summary
NRXP Quant Ranking